Inhibition of Forskolin-stimulated cardiac adenylate cyclase activity by short-chain alcohols  by Robberecht, Patrick et al.
Volume 154, number 1 FEBS LETTERS April 1983 
Inhibition of Forskolin-stimulated cardiac adenylate cyclase 
activity by short-chain alcohols 
Patrick Robberecht, Magali Waelbroeck, Pierre Chatelain, Jean-Claude Camus and 
Jean Christophe* 
Department of Biochemistry and Nutrition, Medical School, Universite’ Libre de Bruxelles, Bld. de Waterloo 115, 
B-l 000 Brussels, Belgium 
Received 21 February 1983 
The diterpene forskolin stimulated rat cardiac adenylate cyclase activity at least 20-fold and potentiated 
the effect of NaF. The stimulatory effect of forskolin was reduced in the presence of Gpp(NH)p. Ethanol 
markedly reduced the stimulation of adenylate cyclase by forskolin while potentiating NaF and Gpp(NH)p 
stimulation. The inhibitory effect of ethanol on forskolin stimulation appeared to be of a mixed type with 
both a competitive and a non-competitive component. Three other short-chain linear alcohols (methanol, 
propanol, butanol) also inhibited forskolin-stimulation, this effect being proportional to the number of 
carbon atoms. 
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1. INTRODUCTION 
This study aimed to evaluate, in rat cardiac 
membranes, the effect of short-chain alcohols on 
the stimulation of adenylate cyclase activity by the 
diterpene forskolin, a potent general activator of 
the enzyme [1,2]. This study was justified on 
theoretical and practical grounds: 
mone [7-IO]. Furthermore, the effects of forskolin 
and alcohol observed in both intact cells and mem- 
branes are immediately reversible (8,111. Finally, 
forskolin and alcohol are hydrophobic molecules. 
(2) In most in vitro studies, forskolin is dissolved 
in ethanol and it was important to evaluate the ef- 
fect of the solvent on the biological activity of the 
diterpene. 
(1) There are some similarities in the proposed 
site(s) of action of forskolin and alcohols on 
adenylate cyclase activity. Forskolin is supposed to 
act directly on the catalytic subunit of adenylate 
cyclase [3] and also on the coupling mechanism of 
guanine nucleotide regulatory sites (N, and Ni) 
with the catalytic subunit [4-61. Alcohol stimula- 
tion of adenylate cyclase activity in membrane 
preparations is obvious when tested in the presence 
of Gpp(NH)p and NaF but more difficult to 
demonstrate when tested in the presence of hor- 
2. MATERIALS AND METHODS 
* To whom correspondence should be addressed 
Abbreviation: GPPPJWP, guanosine 5’-o- 
(2-3-imido)-triphosphate 
Cardiac membranes were prepared from male 
rat hearts as in [12] and stored in liquid nitrogen 
until use at 6 mg protein/ml. Adenylate cyclase ac- 
tivity was determined with minor modifications of 
the procedure in [12,13]. Forskolin was obtained 
from Calbiochem-Behring Corp. (La Jolla CA). A 
30 mM forskolin solution was prepared in absolute 
ethanol and further diluted in distilled water so 
that control experiments always had < 0.08 M 
ethanol. It was verified that adenylate cyclase ac- 
tivity was linear with time under all conditions 
tested. 
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3. RESULTS 
Basal cardiac adenylate cyclase was stimulated 
4.4-, 9.7- and 21 .O-fold by, respectively, maximally 
effective concentrations of Gpp(NH)p and NaF, 
and a submaximal concentration of forskolin 
(table 1). The activity measured when forskolin 
and NaF were added simultaneously was higher 
than the sum of the individual effects; by contrast, 
the activity was lower than the sum of the in- 
dividual effects when forskolin and Gpp(NH)p 
were added in combination, suggesting that car- 
diac membranes contain inhibitory guanine 
nucleotide regulatory proteins [5]. 
Ethanol at 0.1-l .O M was without significant 
effect on basal adenylate cyclase activity but 
markedly potentiated NaF as well as Gpp(NH)p 
stimulations. By contrast, ethanol markedly in- 
hibited forskolin stimulation when tested in the 
same concentration range (fig. 1). Dose-effect 
curves of forskolin activation of adenylate cyclase 
in the presence of increasing concentrations of 
ethanol revealed a progressive decrease in the max- 
imal efficacy of the diterpene as well as a small but 
significant shift to the right of the concentration 
required for half-maximal enzyme stimulation 
(fig.2). These results suggest hat the ethanol in- 
Table 1 
Additions (n) Adenylate 
cyclase 
activity 
Basal 
GPP(NH)P 100 PM 
NaF 10 mM 
Forskolin 30 /cM 
Forskolin 30,uM + 
(11) 25* 1 
(7) 111 f 5 
(7) 243 + 13 
(11) 525 + 18 
GPP(NH)P 100 PM 
Forskolin 30,uM + 
(7) 478 f 16 
NaF 10 mM (7) 1008 f 35 
Adenylate cyclase activity was expressed in pm01 cyclic 
AMP produced. min-’ .mg membrane protein-’ in the 
presence of Gpp(NH)p, NaF and forskolin either alone 
or in combination with Gpp(NH)p or NaF; (n) no. expt. 
The values were the mean + SEM. All stimulators 
effects were significant but that observed when forskolin 
and Gpp(NH)p were added in combination was 
significantly lower than that observed with forskolin 
alone. 
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Fig. 1, Effect of increasing concentrations of ethanol on 
basal (0), and on 100 pM Gpp(NH)p- (o), 10 mM NaF- 
(A) and 30pM forskolin- (x) stimulated adenylate 
cyclase activity in rat heart membranes. The data are 
expressed as a percentage of the value observed for each 
stimulant in the absence of ethanol and are the means of 
at least 3 expt. 
hibition of forskolin-stimulated adenylate cyclase 
activity was of a mixed type, involving a com- 
petitive and a non-competitive mechanism. The ex- 
istence of a competitive factor is supported in 
fig.3: the [ethanol] required for a 50% inhibition 
of forskolin-stimulated adenylate cyclase was 
significantly higher in the presence of 30pM for- 
skolin than in the presence of 1 PM forskolin. 
The linear short-chain alcohols methanol, pro- 
panol and butanol were also able to inhibit for- 
skolin stimulation (fig.4), their efficacy being 
directly related to the chain length. It was also 
observed that each alcohol concentration produc- 
ing a 50% inhibition of forskolin-stimulated 
adenylate cyclase activity was able to potentiate the 
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Fig.2. Dose-effect curves of stimulation of rat heart 
adenylate cyclase by forskolin in the absence (0) or 
presence of 0.2 M (+), 0.4 M (A) and 1.0 M (0) 
ethanol. The results, expressed in cyclic AMP 
produced. min-' . mg membrane protein-’ (after 
subtraction of the basal value) were the means of 3 expt. 
(4) [forskolin] required for half-maximal stimulation. 
in 
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Fig.3. Inhibitory effects of increasing [ethanol] on rat 
heart adenylate cyclase activity stimulated by 1 PM (0) 
and 30 /cM (0) forskolin. The data are expressed as a % 
of the value observed in the absence of ethanol and are 
the means of 3 expt. 
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Fig.4. Inhibitory effects of increasing concentrations of 
methanol (0), ethanol (o), propanol (A) and butanol 
(0) on rat heart adenylate cyclase activity stimulated by 
30pM forskolin. The data are expressed as a % of the 
value observed in the absence of alcohol and are the 
means of 2 expt. 
stimulatory effect of Gpp(NH)p and NaF on 
adenylate cyclase (not shown). 
4. DISCUSSION 
Alcohols cause biological and artificial mem- 
branes to expand and become more fluid [ 141. This 
effect possibly mediates adenylate cyclase activa- 
tion [15,16] and inactivation [8,9], depending on 
the alcohol concentration and the coupling state of 
adenylate cyclase components. Although their 
ultimate effects are on proteins, part of the mode 
of action of alcohols is thought to be mediated by 
their interactions with lipids [17]. 
These results show that 4 short-chain linear 
alcohols inhibited forskolin-stimulated adenylate 
cyclase at concentrations potentiating stimulatory 
effects of NaF and Gpp(NH)p. The efficacy of the 
alcohols tested for inhibiting forskolin-stimulated 
adenylate cyclase activity was related to their chain 
length (i.e., to their partition coefficient) sug- 
gesting that the inhibition was related to their in- 
teraction with hydrophobic sites and possibly 
through a general perturbation in membrane 
dynamics. 
Forskolin is, like alcohol, an amphiphilic 
hydrophobic compound and could conceivably act 
on the lipid matrix of cell membranes. Recent data 
comparing the efficacy of forskolin analogs as in- 
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hibitors of human platelet aggregation [18] argue, 
however, against this interpretation. As forskolin 
activity is highly dependent on the presence of 
hydroxyl groups in a proper position, it is tempting 
to hypothesize that the diterpene is incorporated 
into the membrane bilayer at the interphase bet- 
ween adenylate cyclase components and lipids, so 
that active hydroxyl groups are in a critical con- 
figuration. Alcohols might then inhibit this posi- 
tioning of forskolin as suggested by the mixed-type 
inhibition documented here. 
Whatever the precise site of action of forskolin 
and alcohols, our data are of great practical in- 
terest. Forskolin is usually dissolved in ethanol and 
the diterpene effects are tested in the presence of 
ethanol concentrations that interfered significantly 
with drug activity in our system (dose-effect 
curves of forskolin were for instance obtained in 
the presence of 4070-0.8 M ethanol in [19]). Thus, 
the values of Kact and maximal efficacy of for- 
skolin reported in the literature must be critically 
controlled. 
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